Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.82 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 10.02 | 5.74 | 20.65 | 11.10 | 20.11 | 14.08 | 7.75 | 12.56 | 9.67 | 5.38 | 10.49 | 11.83 | 19.22 | 26.37 | 61.80 | 59.11 | 14.95 | 13.49 | 13.11 | 321.30 | 123.35 |
| — | -59.2% | +166.5% | -11.7% | +107.9% | +161.9% | -26.2% | +6.2% | -49.7% | -79.6% | -83.0% | -80.0% | +28.5% | +95.5% | +371.2% | -81.6% | -87.9% | -92.1% | — | — | — | |
| P/B Ratio | 2.64 | 2.57 | 3.94 | 3.59 | 3.50 | 2.73 | 1.64 | 2.36 | 5.33 | 3.85 | 4.97 | 3.40 | 2.15 | 2.55 | 2.94 | 4.29 | 0.82 | 0.64 | 0.64 | 5.04 | 4.46 |
| — | -5.8% | +139.9% | +52.1% | -34.4% | -29.0% | -66.9% | -30.5% | +148.4% | +51.2% | +69.2% | -20.9% | +160.8% | +298.8% | +355.5% | -14.8% | -81.6% | -83.2% | -88.9% | +65.5% | +26.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.97 | — | — | — | — | 40.07 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.0% | 91.9% | 65.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | -8.1% | -34.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | |
| Operating Margin | -275.9% | -100.7% | -671.4% | -194.0% | -387.1% | -320.9% | -239.3% | -234.1% | -226.8% | -57.1% | -181.5% | -190.9% | -539.5% | -708.8% | -1347.1% | -1028.9% | -2232.3% | -1538.6% | -1384.6% | -3902.7% | -1257.1% |
| — | +68.6% | -180.5% | +17.1% | -70.7% | -462.0% | -31.9% | -22.6% | +58.0% | +91.9% | +86.5% | +81.4% | +75.8% | +53.9% | +2.7% | +73.6% | -77.6% | +23.8% | — | — | — | |
| Net Margin | -265.2% | -99.6% | -658.3% | -190.3% | -377.6% | -319.1% | -223.0% | -216.0% | -211.0% | -42.7% | -172.1% | -167.0% | -416.8% | -643.0% | -1281.6% | -1098.0% | -2625.9% | -1331.4% | -1146.1% | -4103.8% | -1299.4% |
| — | +68.8% | -195.1% | +11.9% | -79.0% | -647.3% | -29.6% | -29.4% | +49.4% | +93.4% | +86.6% | +84.8% | +84.1% | +51.7% | -11.8% | +73.2% | -102.1% | +44.7% | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -54.1% | -14.5% | -26.9% | -14.3% | -15.1% | -14.9% | -11.4% | -15.6% | -25.7% | -7.4% | -18.4% | -11.6% | -11.4% | -14.5% | -14.2% | -20.3% | -30.8% | -14.6% | -13.2% | -15.1% | -12.3% |
| — | +2.7% | -135.8% | +8.3% | +41.2% | -101.0% | +38.0% | -34.5% | -126.3% | +49.0% | -29.0% | +42.9% | +63.1% | +0.9% | -7.8% | -34.2% | -151.2% | +18.5% | +33.4% | +21.6% | +31.4% | |
| ROA | -26.5% | -7.2% | -11.0% | -6.4% | -7.2% | -7.5% | -6.0% | -6.3% | -6.6% | -2.1% | -5.4% | -3.6% | -3.8% | -5.2% | -5.4% | -9.1% | -15.5% | -7.4% | -7.1% | -9.0% | -8.4% |
| — | +4.3% | -84.9% | -0.9% | -8.5% | -262.0% | -11.5% | -75.2% | -72.4% | +60.4% | +1.3% | +60.1% | +75.3% | +29.6% | +23.1% | -0.8% | -84.3% | +36.4% | +36.0% | +21.4% | +35.0% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -103.1% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +31.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.17 | 0.36 | 0.28 | 0.26 | 0.22 | 0.19 | 0.18 | 0.63 | 0.54 | 0.51 | 0.48 | 0.46 | 0.42 | 0.36 | 0.33 | 0.34 | 0.70 | 0.60 | 0.53 | 0.28 |
| — | -26.0% | +90.3% | +61.6% | -59.5% | -58.2% | -62.5% | -63.2% | +37.7% | +28.5% | +39.8% | +44.7% | +33.3% | -40.3% | -39.5% | -38.2% | +23.1% | +132.7% | -13.5% | -12.0% | -43.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.09 | 3.49 | 2.48 | 3.09 | 3.36 | 3.76 | 4.10 | 3.95 | 2.33 | 2.73 | 3.11 | 3.54 | 4.68 | 5.71 | 8.25 | 7.36 | 3.86 | 5.93 | 7.27 | 6.94 | 5.10 |
| — | -7.1% | -39.4% | -22.0% | +44.1% | +37.6% | +31.5% | +11.8% | -50.2% | -52.2% | -62.3% | -51.9% | +21.2% | -3.8% | +13.5% | +6.1% | -24.4% | -48.9% | +4.7% | -10.7% | -40.1% | |
| Quick Ratio | 3.09 | 3.49 | 2.48 | 3.09 | 3.36 | 3.76 | 4.10 | 3.95 | 2.33 | 2.73 | 3.11 | 3.54 | 4.68 | 5.71 | 8.25 | 7.36 | 3.86 | 5.93 | 7.27 | 6.94 | 5.10 |
| — | -7.1% | -39.4% | -22.0% | +44.1% | +37.6% | +31.5% | +11.8% | -50.2% | -52.2% | -62.3% | -51.9% | +21.2% | -3.8% | +13.5% | +6.1% | -24.4% | -48.9% | +4.7% | -10.7% | -40.1% | |
| Interest Coverage | -45.75 | — | — | — | — | — | — | — | — | -1113.88 | -2664.39 | -3.68 | -700.04 | -8521.28 | -17.26 | -10.15 | — | — | -20.73 | -912.00 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRQR stock.
ProQR Therapeutics N.V.'s current P/E is -3.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ProQR Therapeutics N.V.'s current operating margin is -275.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ProQR Therapeutics N.V.'s business trajectory between earnings reports.